Catherine Yue, PhD

Catherine Yue, PhD

Catherine joined Pappas Capital in 2022 as an Associate. She brings to the table her experience as an entrepreneur, a startup ecosystem builder, a commercialization specialist, and an angel investor, especially in the deeptech area, as well as her deep understanding of the Asian startup ecosystem. Catherine is an engineer by training and after obtaining her PhD, she worked as a specialist in a state-owned utilities company to support plant operation, project bidding, technology evaluation and customer acquisition. She then gained knowledge on cross-border technology transfer between Singapore and China while working for a China-related technology transfer company in Singapore. Catherine's most recent involvement prior to joining Pappas was as Senior Incubation Director at a Singapore-based incubator, where she used her 10 years of experience to guide early start-ups in terms of product definition and design, early customer identification and support, market assessment, and financial analysis and planning. She also invested in deeptech companies as an angel investor. Catherine is an ESG advocate and has obtained her ESG Investing certificate from CFA Institute.

Education:
National University of Singapore (B.Eng in Environmental Engineering)
National University of Singapore (PhD in Environmental Engineering)

Brian Gibbs, PhD

Brian joined Pappas Capital in September 2022 as an Investment Analyst and Deal Flow Manager where he participates actively in deal flow management, investment opportunity evaluation, management of key strategic partnerships and identification of opportunities of strategic interest.

Prior to joining Pappas Capital, he was a Venture Analyst at Kineticos Ventures where he participated in investment opportunity evaluation and due diligence, and led the technology transfer outreach program to identify early-stage life science technologies from academic institutions. Prior to Kineticos, Brian worked as a Business Analyst at Johns Hopkins Technology Ventures in Baltimore, MD, where he managed a portfolio of technologies in oncology, neurology, research tools and stem cells for licensing, and assisted faculty in startup formation. Earlier in his career, he was a scientific advisor at Wilson Sonsini where he drafted patent applications and conducted patent landscape and freedom to operate analyses.

Brian completed his doctorate at the University of North Carolina at Chapel Hill and was involved in research projects in genetics, congenital heart diseases and regenerative medicine. Brian also completed postdoctoral fellowships at the University of Pittsburgh, and at the Johns Hopkins School of Medicine in the Department of Cardiology where he studied cardiac regeneration and renewal during heart formation.

Education:
University of North Carolina at Chapel Hill (Ph.D.)
Stillman College (BS in Biology)

Drew Cutshaw, MD

Drew joined Pappas Capital in January 2020 as a Venture Fellow where he participated actively in investment opportunity evaluation, due diligence and deal flow management. Prior to joining Pappas Capital full-time, he worked as a resident physician in surgery at Washington University in St. Louis. He completed his medical degree at the University of North Carolina at Chapel Hill and was involved in research projects in otolaryngology, neurosurgery and medical education, and was elected to Alpha Omega Alpha Honor Society. He also completed his MBA at UNC, earning concentrations in both Healthcare and Entrepreneurship/Venture Capital. He previously completed a research fellowship with Duke University Neurosurgery focusing on development of novel treatments for meningitis and neurologic cancers before medical school. He was a recipient of the Howard Hughes Summer Research Fellowship while at Duke University, with his research focusing on neurobiological basis of drug sensitization.

Education:
University of North Carolina at Chapel Hill (MD)
Kenan-Flagler Business School at University of North Carolina at Chapel Hill (MBA)
Duke University (BS in Neuroscience)

Elizabeth Kelly

Elizabeth joined Pappas Capital in 2021. Prior to joining Pappas, she consulted for early-stage life sciences and technology companies, coaching, and advising management teams on fundraising, growth, competitive and business development strategies. Elizabeth was previously part of the investment team at Echo Health Ventures, and its predecessor, Mosaic Health Solutions, both subsidiaries of Blue Cross NC. She worked on all aspects of the investment process, from identifying and evaluating digital health investment opportunities, to closing transactions and working with portfolio companies to accelerate growth strategies. Elizabeth structured the merger of Mosaic and Cambia Health Solutions’ investment teams that resulted in the launch of Echo in 2016. In addition, she took on an interim role advising Blue Cross NC on corporate development initiatives, contributing financial and operational expertise to set-up a payer-provider joint venture. Prior to Mosaic, Elizabeth had a variety of cross-functional responsibilities at Chimerix (NASDAQ: CMRX), a biopharmaceutical company developing antiviral therapies. In addition to playing a leadership role in the company’s 2013 IPO, she spearheaded activities in corporate development, finance, marketing, IR, and PR. She began her career as an Analyst at Pappas Ventures, where she managed the deal flow process and supported fundraising efforts for a $102 million new venture fund.

Education:

University of North Carolina at Chapel Hill – Kenan-Flagler Business School (MBA in Finance, Entrepreneurship)
University of North Carolina at Chapel Hill (BA in Management, Spanish)

Bert Kinsey, PhD, PharmD

Bert joined Pappas Capital in 2020 and brings significant experience in translational biomedical research and biotechnology equity research. Prior to joining Pappas, he spent two years at RBC Capital Markets in New York City as a Senior Associate on an Institutional Investor-ranked equity research team covering large-, mid- and small-cap biotechnology companies. At RBC he gained experience building and maintaining financial models, vetting public and private biotechnology companies to support investment banking, and conducted clinical and commercial diligence to shape investment theses. Prior to RBC, Bert was Associate Professor of Medicine at the University of Virginia (UVA) where he established an independent research laboratory investigating the role of the immune system in different forms of kidney disease. Throughout his 10 years at UVA, his laboratory was consistently funded by the NIH, including R01, R21, K01 and F32 grants focused on the role of regulatory T cells in acute kidney injury. His academic experience included in vitro and in vivo preclinical experimentation, as well as translational clinical research in cardiac surgery patients.

Bert currently serves as an observer for CuraSen, OrphoMed and Ribometrix, and previously served as an observer for Reneo Pharmaceuticals.

Education:

Medical University of South Carolina (PhD in Pharmaceutical and Biomedical Sciences)
Medical University of South Carolina (Doctor of Pharmacy/PharmD)